RxDoctor Payments Data

Greggory Gahn, MD

Retina Specialist · Reno, NVNPI 1720541147

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (37.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Genentech USA, Inc. at 48.0% of the total. 2025 is the largest year on record at $7,291, more than ten times the $146 reported in 2020.

$14,516in general payments, 2019–2025

Across 141 payments — averaging $102.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$7K
  • Alcon$3K
  • Bausch & Lomb Americas Inc.$2K
  • Astellas Pharma US Inc$715
  • AbbVie$317
  • Glaukos Corporation$257
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$5,47538%
  • Travel & lodging$3,59025%
  • Food & beverage$5,35137%
  • Education$1001%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$8,975
Medicare patients
46
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate228$9,227
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat54$856
MoxifloxacinMoxifloxacin Hcl15$363
ErythromycinErythromycin Base31$355
Timolol Maleate17$207
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha17$167
Brimonidine Tartrate19$115

Paid to pharmacies, not to this prescriber.

Other retina specialist in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →